Journal
NEUROBIOLOGY OF AGING
Volume 76, Issue -, Pages 24-34Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2018.11.026
Keywords
Alzheimer; tau; Modulator; Cell screening; Pathway analysis; tau aggregation
Categories
Funding
- DZNE
- MPG
- Katharina-Hardt Foundation
- iDSN
- HUMIT grant (BMBF)
Ask authors/readers for more resources
We have developed a cell-based phenotypic automated high-content screening approach for N2a cells expressing the pro-aggregant repeat domain of tau protein (tau(RD Delta K)), which allows analysis of a chemogenomic library of 1649 compounds for their effect on the inhibition or stimulation of intracellular tau aggregation. We identified several inhibitors and stimulators of aggregation and achieved a screening reproducibility >85% for all data. We identified 18 potential inhibitors (= 1.1% of the library) and 10 stimulators (= 0.6% of the library) of tau aggregation in this cell model of tau pathology. The results provide insights into the regulation of cellular tau aggregation and the pathways involved in this process (e.g., involving signaling via p38 mitogen-activated protein kinase, histone deacetylases, vascular endothelial growth factor, rho/ROCK). For example, inhibitors of protein kinases (e.g., p38) can reduce tau aggregation, whereas inhibitors of deacetylases (histone deacetylases) can enhance aggregation. These observations are compatible with reports that phosphorylated or acetylated tau promotes pathology. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available